Franck Grimaud, CEO of Vivalis, said: “Vivalis is pleased to enter in this agreement to support Acambis’s R&D efforts for the development of new vaccines.
“With already more than 30 different vaccines evaluated or developed on Vivalis eb66 cell line, we strongly believe that this cell line has the potential to replace the eggs, and to become a standard cell substrate for vaccines production in the foreseeable future.”